Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R21AI179276-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Human Sciences Research Council | OTHER_GOV |
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
Not provided
Not provided
Not provided
This study will compare community-delivered, multi-month dispensing of tuberculosis preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of South African adults who are recommended to receive TB preventive therapy.
We hypothesize that persons receiving multi-month dispensing of TPT in the community will have a higher rate of TPT completion at 3 months than persons receiving TPT via standard of care with monthly clinic-based refills.
The research objective is to understand and overcome key barriers to tuberculosis preventive therapy (TPT) delivery and completion in South Africa in the setting of 3HP scale-up. (3HP: short-course TPT consisting of 3 months weekly isoniazid[H] plus rifapentine [P]). The study will investigate these factors through a trial comparing community-delivered TPT, to clinic-based TPT and qualitative research investigating barriers to TPT completion and exploring task-shifted TPT delivery.
Aim 1: To determine the effect of community-based initiation and delivery of TPT on TPT completion.
Hypothesis: Community-delivered TPT will be associated with higher initiation and completion of TPT than standard of care clinic-based TPT.
Approach: Persons eligible for TPT will be identified through the Triage+ TB study and other community-based TB screening activities. Eligible persons will be randomized at the household level to 1) Immediate initiation of TPT & full 12 weeks delivery at once, or 2) Immediate initiation of TPT, 2-week supply, and referral to clinic for TPT completion. TPT adherence and completion will be measured by a combination of self-report, pill count, and serum drug level indicators.
Aim 2: To determine factors associated with TPT initiation and completion in people eligible for TPT identified in community settings.
Hypothesis: People with HIV (PWH) will have better rates of initiation and completion of TPT than people without HIV.
Approach: Participant interviews and surveys at baseline and end-of-study will assess willingness to take TPT, barriers and facilitators for individuals, experience taking TPT, and experience of interactions in clinic settings. Focus groups will be purposively selected based on end-of-study survey responses to elicit factors determining patient experience.
Aim 3: To determine feasibility and acceptability of differentiated service delivery (DSD) approaches, including task-shifting, for TPT delivery and scale-up.
Hypothesis: DSD TPT will be feasible and acceptable. Approach: Participatory qualitative research, and implementation science approaches including workflow mapping will be used to assess clinician-level barriers and inefficiencies in providing clinic-based TPT. In-depth interviews and focus groups will be conducted with pharmacy assistants, nurses, clinic operational managers, and district program managers to assess acceptability. Clinic flow will be mapped to determine effect of task-shifted pharmacy assistant TPT delivery on workflow and patient experience in the clinic.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Investigational: Community-based TB preventive therapy (TPT) | Other | Participants in the community arm will receive a multi-month dispensing packet at enrollment with the complete 3 month supply of TPT (3HP: 3 months of weekly isoniazid and rifapentine). |
|
| Standard-of-Care Tuberculosis Preventative Therapy (TPT) | Active Comparator | Participants in the standard of care arm will receive a referral letter to their local Department of Health (DoH) clinic to continue TPT. They will be instructed to present to the DoH clinic within 2 weeks to receive their continuation doses of TPT per current South African DoH standard of care (refills administered monthly). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP) | Other | Participants randomized to this arm will receive the entire supply of TB preventive therapy (TPT) at enrollment. |
| Measure | Description | Time Frame |
|---|---|---|
| Completion of a course of TB preventive therapy (TPT) | TPT completion defined as taking 11 doses of 3HP (3 months weekly isoniazid [H] plus rifapentine [P] ) within 16 weeks of 3HP initiation. The outcome will be measured as a composite outcome including: self-report of doses taken, periodic pill counts, one-time serum drug level of isoniazid. | 3 months, extended to 16 weeks as needed |
| Measure | Description | Time Frame |
|---|---|---|
| Overall adherence with TPT | Proportion of doses completed | 3 months, extended to 16 weeks as needed |
| Predictors of TPT adherence | 3 months, extended to 16 weeks as needed |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adrienne E Shapiro, MD, PhD | University of Washington | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Human Sciences Research Council | Sweetwaters | KwaZulu-Natal | South Africa |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40803739 | Derived | Misra S, Madonsela T, Thomas KK, Grabow C, Lenn M, Morton JF, Reither K, Lynen L, van Heerden A, Essack Z, Bosman S, Shapiro AE. ThiPhiSA: new pathways to TB prevention from community screening - a household-randomised controlled trial in KwaZulu-Natal, South Africa. BMJ Open. 2025 Aug 12;15(8):e100927. doi: 10.1136/bmjopen-2025-100927. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 29, 2026 | |
| Reset | Jun 24, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 29, 2026 | Jun 24, 2026 | |||
| Jul 2, 2026 |
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C026677 | 9 alpha,11 alpha,15 alpha-trihydroxy-16-phenoxy-17,18,19,20-tetranorprosta-4,5,13-trienoic acid |
| C018421 | rifapentine |
Not provided
Not provided
Not provided
Household-level randomization -- all individuals in a household will be randomized to the same study arm of medication delivery.
Not provided
Not provided
Not provided
Not provided
| Clinic-link TPT | Other | Participants receive 2-week supply of TPT at initiation, then continue to receive remainder of TPT course at clinic (including refills). |
|
| Participant satisfaction with the assigned TPT delivery method | assessed by questionnaire | 3 months, extended to 16 weeks as needed |
| Adverse events | Assessed by adverse event reporting | 3 months, extended to 16 weeks as needed |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |